Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Saim Kerman"'
Autor:
Akif Akbulat, Guvenc Kockaya, Nedim Durmus, Saim Kerman, Mehmet Emin Buyukokuroglu, İsmail Mert Vural, Pelin Tanyeri
Publikováno v:
Sakarya Tıp Dergisi, Vol 8, Iss 4, Pp 847-853 (2018)
Bu çalışmanın amacı, Türkiye’de meme kanseri tedavisinde ruhsatsız ve endikasyon dışı ilaç kullanımını değerlendirmektir. Bu çalışmaya trastuzumab veya diğer endikasyon dışı ilaç kullanımı için başvuruda bulunan olan ErbB
Externí odkaz:
https://doaj.org/article/4a5adb2f52fe44d9a52a3b598761c650
Autor:
Guvenc Kockaya, Kagan Atikeler, Esin Tuna, Pelin Kılıc, Pelin Tanyeri, Nurcan Umman, İsmail Mert Vural, Omer Altun, Akif Akbulat, Guven Artiran, Ercan Simsek, Hakkı Gursoz, Saim Kerman
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 2, Pp 99-103 (2013)
OBJECTIVES: General Directorate of Pharmaceuticals and Pharmacy (IEGM) is responsible for setting all prices for human medicinal products. The reference pricing system is used for setting these prices. Reference countries are reviewed annually and ma
Externí odkaz:
https://doaj.org/article/9f6d1406e87e43f8847456784b07372f
Autor:
Guvenc Kockaya, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz, Saim Kerman
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 1, Pp 19-25 (2013)
OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% of whom are diag
Externí odkaz:
https://doaj.org/article/e863411673a44bb381b6e59e90c497de
Introduction and utilisation of high priced HCV medicines across Europe; implications for the future
Autor:
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, Hanne Bak Pedersen, Ali Alkan, Patricia Vella Bonanno, Ljiljana Sović Brkičić, Anna Bucsics, Guillame Dedet, Jaran Eriksen, Joseph O Fadare, Jurij Fürst, Gisselle Gallego, Isabella Piassi Godói, Augusto Afonso Guerra Junior, Hakki Gürsöz, Saira Jan, Jan Jones, Saim Kerman, Roberta Joppi, Ott Laius, Newman Madzikwa, Einar Magnusson, Mojca Maticic, Vanda Markovic-Pekovic, Amos Massele, Olayinka Ogunleye, Aisling O’Leary, Jutta Piessnegger, Catherine Sermet, Steven Simoens, Celda Tiroyakgosi, Ilse Truter, Magnus Thyberg, Kristina Tomekova, Magdalene Wladysiuk, Sortiris Vandoros, Elif Hilal Vural, Corinne Zara, Brian Godman
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 20
Externí odkaz:
https://doaj.org/article/442ad35f14564b47bc0809c09511b491
Autor:
Mehmet Emin Buyukokuroglu, Saim Kerman, Güvenç Koçkaya, Mehmet Hanifi Tanyeri, Pelin Tanyeri, I.M. Vural
Publikováno v:
European Archives of Medical Research. 35:19-22
Autor:
Nedim Durmus, Saim Kerman, Güvenç Koçkaya, Pelin Tanyeri, I.M. Vural, Akif Akbulat, Mehmet Emin Buyukokuroglu
Publikováno v:
Sakarya Medical Journal. 8:847-853
Bu calismanin amaci, Turkiye’de meme kanseri tedavisinde ruhsatsiz ve endikasyon disi ilac kullanimini degerlendirmektir. Bu calismaya trastuzumab veya diger endikasyon disi ilac kullanimi icin basvuruda bulunan olan ErbB-2 pozitif tumorleri olan m
Autor:
I.M. Vural, Mehmet Hanifi Tanyeri, Mehmet Emin Buyukokuroglu, Pelin Tanyeri, Güvenç Koçkaya, Saim Kerman, Turkish Drug
Publikováno v:
European Archives of Medical Research.
Autor:
I. Mert Vural, Güvenç Koçkaya, Saim Kerman, Pelin Kilic, Guven Artiran, Akif Akbulat, Albert I. Wertheimer, Pelin Tanyeri
Publikováno v:
Value in Health Regional Issues. 4:47-52
Background: The health policies of many countries and regions have already defined orphan drugs for rare diseases. Although there is no official definition of orphan drugs in Turkey, all orphan drugs are covered by reimbursement, regardless of their
Autor:
Demet Aydinkarahaliloglu, Yelda Kasap, Oguzhan Koyuncu, Nedim Durmus, Gamze Ozbilen, Guven Artiran, Saim Kerman, Osman Yildirim
Publikováno v:
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 23:149-154
OZET: Turkiye'de tianeptinin kotuye kullanim risk yonetimi: Ulusal bir tecrube Amac: Major depresif ataklarin tedavisinde kullanilan tianeptin, herhangi bir ilac veya alkol bagimliligi veya kotuye kullanimi oykusu olanlarda bagimlilik potan- siyeli o
Autor:
Pelin Tanyeri, Akif Akbulat, Ercan Simsek, Güvenç Koçkaya, Omer Altun, Saim Kerman, I.M. Vural, K. Atikeler, Nurcan Umman, Guven Artiran, Pelin Kilic, E Tuna, Hakkı Gürsöz
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 2, Pp 99-103 (2013)
OBJECTIVES: General Directorate of Pharmaceuticals and Pharmacy (IEGM) is responsible for setting all prices for human medicinal products. The reference pricing system is used for setting these prices. Reference countries are reviewed annually and ma